TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06469879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450+Anlotinib
Description: TQB2450 injection test group, 1200 mg/time, strength: 600mg/20 mL, intravenous drip, day 1, every 3 weeks. Anlotinib hydrochloride capsules: 8 mg/time, strength: 10mg/capsule, 8mg/capsule, 6mg/capsule., 1 time a day (QD), continuous use for 2 weeks and stop for 1 week.~TQB2450 Injection Placebo (control group): 0 mg/time, strength: 0mg/20 mL, Intravenous Drip, Day 1, every 3 weeks. Anlotinib hydrochloride capsule placebo: 0 mg/time, strength: 0mg/capsule, 1 time a day (QD), continuous use for 2 weeks and stop for 1 week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQB2450 placebo + Anlotinib placebo
Description: No drug substance is contained
Study: NCT04784195

Intervention type: BEHAVIORAL
Intervention: Observation
Description: Verification of morfology and functionality of neck muscles
Study: NCT06032351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Innovation-integrated curriculum for dementia care and care management
Description: The curriculum integration group will receive two intervention phases, including an innovation-integrated curriculum for dementia care and an innovation-integrated curriculum for care management with Entrustable Professional Activities (EPAs), lectures, Situated Simulation Learning, Team-based learning, and Objective Structured Clinical Examination(OSCE).

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional classroom teaching course programs
Description: The conventional teaching group will receive only traditional classroom teaching course programs.
Study: NCT06467994

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cashew oral immunotherapy
Description: Cashew Flour (boiled/ roasted) that is prepared under food manufacturing regulations

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral immunotherapy
Description: Placebo oral immunotherapy consists of corn flour with food colouring that has similar appearance, taste and smell to the active product
Study: NCT05009407

Intervention type: BIOLOGICAL
Intervention: Immunohistochemistry and clinical analyses on patients and corneas
Description: Immunohistochemistry and clinical analyses on patients and corneas

Intervention type: BIOLOGICAL
Intervention: Immunohistochemistry and clinical analyses on patients and corneas
Description: Immunohistochemistry and clinical analyses on patients and corneas
Study: NCT05439928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEXCOM G6 CGM
Description: Continuous glucose monitoring
Study: NCT04560023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposition to multimedia content
Description: Video and images watched on a tablet. Patient could decide which information want to watch.
Study: NCT04700566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Renuva Allograft Adipose Matrix
Description: Injection of Renuva Allograft adipose Matrix in the vocal fold for vocal fold medialization and treatment of glottal insufficiency
Study: NCT04958941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Intervention group
Description: During 2 months participants will be able to asses their mood and practice in real time their emotional regulation skills with an ecological momentary interventions APP.
Study: NCT05557149

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality Exposure to Neutral Cues
Description: Virtual reality exposure to neutral stimuli (360 degrees visual and audio immersion with Oculus Quest 2 virtual reality headset). Participants stay sitted on chair and can tilt, rotate and move forward and backward upper body members. No interaction with the investigator during the virtual reality immersion.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Respiratory Relaxation
Description: Respiratory relaxation practise. No interaction with the investigator during the relaxation practise.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure to Cocaine-Related Cues
Description: Virtual reality exposure to cocaine-related stimuli (360 degrees visual and audio immersion with Oculus Quest 2 virtual reality headset). Participants stay sitted on chair and can tilt, rotate and move forward and backward upper body members. No interaction with the investigator during the virtual reality immersion.
Study: NCT04675398

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Summit RC+S
Description: Using the RC+S pulse generator, patients receive clinically-optimized open loop DBS stimulation to the pallidum.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Summit RC+S
Description: Using the RC+S pulse generator, the patients will receive closed-loop stimulation at random time points. These random stimulation times will in total equal the total amount of time of active movement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Summit RC+S
Description: Using the RC+S pulse generator, the patients will receive closed-loop stimulation during time of contralateral limb movement (e.g. left brain stimulation during right leg/arm movement).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Summit RC+S
Description: Using the RC+S pulse generator, the patients will receive closed-loop stimulation during time of no movement for the contralateral limb (e.g. left brain stimulation while right leg/arm is not moving).
Study: NCT06183905

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Prostate imaging
Description: Multiparametric ultrasound (mpUS) The mpUS examinations are performed in the order of greyscale imaging, elastography and contrast-enhanced ultrasound (CEUS), with the patients in the left lateral decubitus position.Greyscale imaging and elastography are evaluated by one radiologist. After standard step-sectional greyscale imaging, transverse elastic images are obtained from the base to the apex by manual compression. The amplitude and frequency of compression are adjusted according to the visual compression indicator on the screen to minimize interoperator variability. CEUS is performed using a bolus of 2.4 mL contrast agents (SonoVue, Bracco) using Contrast mode.~Multiparametric MRI (mpMRI) Prostate mpMRI images were acquired using a 3-T scanner with an external phased-array coil.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostate biopsy
Description: All patients will undergo standard 12-core systematic biopsy (SB) within 1 week following the imaging protocol in conjunction with targeted biopsy (TB) for suspicious lesions on mpUS and/or mpMRI. First, 12-core SB is performed, followed by cognitive mpUS-TB with 2-3 cores for each suspicious lesion. The suspicious lesions on mpUS include hypoechoic lesion(s) on greyscale imaging, reproducible stiff lesion(s) on elastography, and hypoperfused area(s) with ill-defined boundaries or increased focal/asymmetric contrast enhancement on CEUS. Thereafter, MRI/US fusion TB is performed sampling 2-3 cores for each lesion with a Prostate Imaging Reporting and Data System (PI-RADS) version 2 score of 3 or above.Each biopsy sample is placed in the micro-cassette and labelled to identify the biopsy technique and location.
Study: NCT04993807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared decision-making tool
Description: Participants will use an interactive web page intended to aid patient decision-making (i.e., a decision aid) while undergoing consultation for atrial fibrillation ablation.
Study: NCT06339710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benznidazole 300 mg daily 8 weeks
Description: 672 participants will be randomly assigned to receive the standard-dose of benznidazole (300 mg daily for 8 weeks) or the short experimental regimens (benznidazole 300 mg daily for the first 2 weeks plus placebo for the last 6 weeks or benznidazole 300 mg daily for the first 4 weeks plus placebo for the last 4 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benznidazole 300 mg daily 8 weeks
Description: 672 participants will be randomly assigned to receive the standard-dose of benznidazole (300 mg daily for 8 weeks) or the short experimental regimens (benznidazole 300 mg daily for the first 2 weeks plus placebo for the last 6 weeks or benznidazole 300 mg daily for the first 4 weeks plus placebo for the last 4 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benznidazole 300 mg daily 8 weeks
Description: 672 participants will be randomly assigned to receive the standard-dose of benznidazole (300 mg daily for 8 weeks) or the short experimental regimens (benznidazole 300 mg daily for the first 2 weeks plus placebo for the last 6 weeks or benznidazole 300 mg daily for the first 4 weeks plus placebo for the last 4 weeks)
Study: NCT05867914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (iNO)
Description: eNOfit system delivering iNO
Study: NCT06234813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clot formation in whole blood under flow in a microfluidic flow chamber coated with tissue factor and collagen
Description: TTAS (single measurements)~Clot formation in whole blood under flow (2000 s-1) in a microfluidic flow chamber coated with tissue factor and collagen (T-TAS with AR chip)~1. 500 µL of whole blood for each point;~2. 7 points for each condition;~3. Around 4 mL of whole blood will be needed for each patient or healthy subject;~4. Values for Area Under the Curve (Aritrary Unit), Occlusion Starting Time (min), Occlusion Time (min.) will be reported.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clot formation in whole blood under flow in a microfluidic flow chamber coated with tissue factor and collagen
Description: TTAS (single measurements)~Clot formation in whole blood under flow (2000 s-1) in a microfluidic flow chamber coated with tissue factor and collagen (T-TAS with AR chip)~1. 500 µL of whole blood for each point;~2. 7 points for each condition;~3. Around 4 mL of whole blood will be needed for each patient or healthy subject;~4. Values for Area Under the Curve (Aritrary Unit), Occlusion Starting Time (min), Occlusion Time (min.) will be reported.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: : PRP viscoelastic changes under clot formation measured by thromboelastometry using RoTEM
Description: ROTEM (single measurements)~1. ROTEM cups will be added~   * 20 µL calcium reagent (STARTEM)~  * 20 µL of 2,940-fold prediluted r-ExTEM reagent (50,000 fold dilution relative to 340 µL in the cup) added~  * 300 µL spiked PRP at 250 G/L (2.5 mL of PRP/patient)~2. Values for clot time (CT sec, clot formation time (CFT) sec, maximum clot formation (mm) will be reported.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: : PRP viscoelastic changes under clot formation measured by thromboelastometry using RoTEM
Description: ROTEM (single measurements)~1. ROTEM cups will be added~   * 20 µL calcium reagent (STARTEM)~  * 20 µL of 2,940-fold prediluted r-ExTEM reagent (50,000 fold dilution relative to 340 µL in the cup) added~  * 300 µL spiked PRP at 250 G/L (2.5 mL of PRP/patient)~2. Values for clot time (CT sec, clot formation time (CFT) sec, maximum clot formation (mm) will be reported.
Study: NCT05844150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM8002
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV infusion
Study: NCT05495217

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional Laparoscopy
Description: A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY using Induced pneumoperitoneum.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gasless Laparoscopy
Description: A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY without Induced pneumoperitoneum.It mechanically elevates the abdominal wall and allows laparoscopic visualization through a single incision, providing diagnostic and therapeutic procedures.
Study: NCT05114057

Intervention type: OTHER
Group type: OTHER
Intervention: Renal Angina Index (RAI)
Description: Risk-stratification tool using measures of risk and presence of injury to predict Acute Kidney Injury

Intervention type: OTHER
Group type: OTHER
Intervention: Renal Angina Index (RAI)
Description: Risk-stratification tool using measures of risk and presence of injury to predict Acute Kidney Injury

Intervention type: OTHER
Group type: OTHER
Intervention: Renal Angina Index (RAI)
Description: Risk-stratification tool using measures of risk and presence of injury to predict Acute Kidney Injury
Study: NCT05547061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177-DGUL
Description: Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177-DGUL
Description: Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177-DGUL
Description: Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-NGUL
Description: Administered intravenously during screening and every 12 weeks after the first administration of Lu-177-DGUL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-NGUL
Description: Administered intravenously during screening and every 12 weeks after the first administration of Lu-177-DGUL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-NGUL
Description: Administered intravenously during screening and every 12 weeks after the first administration of Lu-177-DGUL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-NGUL
Description: Administered intravenously during screening and every 12 weeks after the first administration of Lu-177-DGUL.
Study: NCT05843201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The AquaPass System
Description: The system is a non-invasive, multiple use device intended for use at the hospital, at the outpatient clinic settings or at home. The system administers warm, dry air around the patients' body in order to create environmental conditions that increase the patients' sweat rate. Throughout the treatment, fluids from the interstitial compartment are removed from the body by the eccrine sweat glands.
Study: NCT06408142

Intervention type: DIAGNOSTIC_TEST
Intervention: HIV testing
Description: Point of Care HIV testing universally regardless of risk factors
Study: NCT05020899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sessions with a trained counselor
Description: 4 sessions will be provided with a trained counselor who will discuss the participant's' smoking habits with them and strategies to help them quit. The first session is in-person, lasts for 20 minutes, and typically happens when the participant comes to the HIV clinic to pick up their medication. Sessions 2 through 4 are over the telephone and last for 15 minutes each. These occur 1 week, 4 weeks, and 8 weeks after the first session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cell phone messages
Description: Brief messages that give tips to help quit smoking will be sent to participants' cell phones using WeChat. 3 messages per day will be sent for the first week, 2 messages per day for the next 3 weeks, 1 message per day for the next 1 week, and 1-2 messages per week for the rest of the time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Offered nicotine replacement therapy
Description: Participants will be offered nicotine replacement therapy (gum or patch, depending on which one is available).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offered nicotine replacement therapy
Description: Participants will be offered nicotine replacement therapy (gum or patch, depending on which one is available).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-help guide for quitting smoking
Description: Participants will be offered a self-help guide with information about quitting smoking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help guide for quitting smoking
Description: Participants will be offered a self-help guide with information about quitting smoking.
Study: NCT05764746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine and Amodiaquine Drug Combination
Description: AL and AQ will be given together for three days then followed by placebo for three days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine then Artesunate amodiaquine
Description: AL will be given twice a day for three days then followed by artesunate amodiaquine once a day for three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: This will be the comparator arm as standard treatment, where only AL will be given twice a day for three days then placebo for three days
Study: NCT05842564

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Blood sample of maximum 20ml (5 tubes of EDTA of 4ml or 5 tubes of EDTA of 2ml and a tube for the conservation of genomic DNA)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood sample of maximum 20ml (5 tubes of EDTA of 4ml or 5 tubes of EDTA of 2ml and a tube for the conservation of genomic DNA)
Study: NCT06234813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrombin Generation Assay (TGA) in PRP using TF trigger
Description: TGA (single measurements)~1. The following will be added to well:~   * 20 uL of PRP-Reagent~  * 80 uL of spiked PRP (600 µL/patient at 100 G/L)~  * 20 uL FluCa~2. Values for thrombin activity versus time and the derived parameters incl. lag-time (min), time to peak (min), time to peak (min), ETP (Arbitrary Unit) will be reported.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thrombin Generation Assay (TGA) in PRP using TF trigger
Description: TGA (single measurements)~1. The following will be added to well:~   * 20 uL of PRP-Reagent~  * 80 uL of spiked PRP (600 µL/patient at 100 G/L)~  * 20 uL FluCa~2. Values for thrombin activity versus time and the derived parameters incl. lag-time (min), time to peak (min), time to peak (min), ETP (Arbitrary Unit) will be reported.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global fibrinolytic capacity in PRP using reagents for in vitro triggering of the clot and its lysis
Description: Global fibrinolytic capacity (Lysis Timer) in 100 µL of PRP (250 G/L) using reagents for in vitro triggering of the clot (thrombin and calcium) and its lysis (tissue-plasminogenactivator (t-PA). Around 1 mL of PRP in total Lysis time in min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Global fibrinolytic capacity in PRP using reagents for in vitro triggering of the clot and its lysis
Description: Global fibrinolytic capacity (Lysis Timer) in 100 µL of PRP (250 G/L) using reagents for in vitro triggering of the clot (thrombin and calcium) and its lysis (tissue-plasminogenactivator (t-PA). Around 1 mL of PRP in total Lysis time in min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concizumab
Description: Thrombin generation assay (TGA), microchip flow-chamber assay (T-TAS, rotational thromboelastometry and global fibrinolytic capacity to investigate and compare the effects of mixing concizumab (200, 1000 and 4000 ng/mL) with the main bleed treatment options for persons with GT
Study: NCT05842564

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsies
Description: 5 biopsies (one for each segment of the intestine explored: ileum, right colon, transverse colon left colon and sigmoid) will be taken during the ileocolonoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: 5 biopsies (one for each segment of the intestine explored: ileum, right colon, transverse colon left colon and sigmoid) will be taken during the ileocolonoscopy
Study: NCT06112522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirbanibulin
Description: Subjects will be given one study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days. Subjects with unresolved lesion at d28 or d56 or d72 or d84 will be given an additional study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days.
Study: NCT05363605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [225Ac]-FPI-1966
Description: \[225Ac\]-FPI-1966 is a targeted alpha therapeutic that consists of vofatamab, a bifunctional chelate, and actinium-225, an alpha particle emitting radionuclide. In Phase 1, the dose depends on cohort assignment. In Phase 2, the RP2D regimen will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [225Ac]-FPI-1966
Description: \[225Ac\]-FPI-1966 is a targeted alpha therapeutic that consists of vofatamab, a bifunctional chelate, and actinium-225, an alpha particle emitting radionuclide. In Phase 1, the dose depends on cohort assignment. In Phase 2, the RP2D regimen will be administered.
Study: NCT04812340

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity circuit training
Description: 6 series with 3 minutes rest between the series. each series will consist of 30 seconds each of burpees, skipping, lunges, 1- legged squat, leg levers, and push-ups with 30 seconds rest in between. the volume of exercise will be increased progressively over a period of 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity interval training
Description: 4 series with 3 minutes rest in between. each series will consist of 10 minutes of jogging and 5 minutes walking with 30 seconds recovery in between. the volume of exercise will be increased progressively over a period of 8 weeks.
Study: NCT06515210

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acacia Gum
Description: Participants (n=23) incorporate the fibre supplement into their usual diet daily.
Study: NCT05363605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [111In]-FPI-1967
Description: \[111In\]-FPI-1967 is an imaging agent that consists of vofatamab, a bifunctional chelate and indium-111 radionuclide. Participants will receive \[111In\]-FPI-1967 Injection of 185 MBq for imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [111In]-FPI-1967
Description: \[111In\]-FPI-1967 is an imaging agent that consists of vofatamab, a bifunctional chelate and indium-111 radionuclide. Participants will receive \[111In\]-FPI-1967 Injection of 185 MBq for imaging.
Study: NCT06515210

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microcrystalline Cellulose
Description: Participants (n=23) incorporate the fibre supplement into their usual diet daily.